Erdafitinib

Erdafitinib
Product Description

Indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC), that has susceptible FGFR3 or FGFR2 genetic alterations, and progressed during or following at least one line of prior platinum-containing chemotherapy, including within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company
Specifications
  • CAS Registry Number
    1346242-81-6

OMGENE LIFE SCIENCES PRIVATE LIMITED

  • IN
  • 2020
    On CPHI since
  • 50 - 99
    Employees
Company types
Pharmaceutical company

More Products from OMGENE LIFE SCIENCES PRIVATE LIMITED (44)

  • Bedaquiline Fumarate

    Product Bedaquiline Fumarate

    Diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary multi-drug resistant tuberculosis (MDR-TB).
  • Binimetinib

    Product Binimetinib

    Indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation
  • Brivaracetam

    Product Brivaracetam

    Indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
  • Carbetocin

    Product Carbetocin

    Used to prevent excessive bleeding after childbirth, particularly following Cesarean section.
  • Crisaborole

    Product Crisaborole

    Indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
  • Deutetrabenazine

    Product Deutetrabenazine

    Indicated for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia in adults.
  • Etelcalcetide

    Product Etelcalcetide

    Iindicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.
  • Everolimus

    Product Everolimus

    Indicated for Prophylaxis of Organ Rejection in Kidney Transplantation and Prophylaxis of Organ Rejection in Liver Transplantation
  • Fulvestrant

    Product Fulvestrant

    Indicated for the treatment of Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression...
  • Ganirelix Acetate

    Product Ganirelix Acetate

    Indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation. Close
  • Ixazomib Citrate

    Product Ixazomib Citrate

    Indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
  • Lanreotide Acetate

    Product Lanreotide Acetate

    Indicated for the long-term treatment of acromegalic patients who have had an inadequate response to surgery and/or radiotherapy, or for whom surgery and/or radiotherapy is not an option.

OMGENE LIFE SCIENCES PRIVATE LIMITED resources (1)